Evidence map›Paper›PMID 36533957›Full record

ArticleCancer science2023

Genetic and phenotypic determinants of morphologies in 3D cultures and xenografts of lung tumor cell lines.

Daisuke Matsubara, Taichiro Yoshimoto, Ninad Akolekar, Takashi Totsuka, Yusuke Amano, Atsushi Kihara, Tamaki Miura, Yuriko Isagawa, Yuji Sakuma, Shumpei Ishikawa and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Daisuke MatsubaraDepartment of Integrative Pathology, Jichi Medical University, Tochigi, Japan.ORCID https://orcid.org/0000-0002-6233-6840
Taichiro YoshimotoDepartment of Integrative Pathology, Jichi Medical University, Tochigi, Japan.ORCID https://orcid.org/0000-0002-4714-5261
Ninad AkolekarSMS Data Tech corporation, Tokyo, Japan.
Takashi TotsukaSMS Data Tech corporation, Tokyo, Japan.
Yusuke AmanoDepartment of Integrative Pathology, Jichi Medical University, Tochigi, Japan.
Atsushi KiharaDepartment of Integrative Pathology, Jichi Medical University, Tochigi, Japan.
Tamaki MiuraDepartment of Integrative Pathology, Jichi Medical University, Tochigi, Japan.
Yuriko IsagawaDepartment of Integrative Pathology, Jichi Medical University, Tochigi, Japan.
Yuji SakumaDepartment of Integrative Pathology, Jichi Medical University, Tochigi, Japan.ORCID https://orcid.org/0000-0003-2298-1359
Shumpei IshikawaDepartment of Preventive Medicine, University of Tokyo, Tokyo, Japan.
Tetsuo UshikuHuman Pathology Department, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Masashi FukayamaHuman Pathology Department, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Toshiro NikiDepartment of Integrative Pathology, Jichi Medical University, Tochigi, Japan.
Jichi Medical University · JPSMC Corporation (Japan) · JPThe University of Tokyo · JPTokyo Medical University · JPUniversity of Tsukuba · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 17K15652Ministry of Education, Culture, Sports, Science and Technology 18H02634Ministry of Education, Culture, Sports, Science and Technology 19K07441Ministry of Education, Culture, Sports, Science and Technology 22H02840Ministry of Education, Culture, Sports, Science and Technology 22K06945
6 · The paper itself

Abstract

We previously proposed the classification of lung adenocarcinoma into two groups: the bronchial epithelial phenotype (BE phenotype) with high-level expressions of bronchial epithelial markers and actionable genetic abnormalities of tyrosine kinase receptors and the non-BE phenotype with low-level expressions of bronchial Bronchial epithelial (BE) epithelial markers and no actionable genetic abnormalities of tyrosine kinase receptors. Here, we performed a comprehensive analysis of tumor morphologies in 3D cultures and xenografts across a panel of lung cancer cell lines. First, we demonstrated that 40 lung cancer cell lines (23 BE and 17 non-BE) can be classified into three groups based on morphologies in 3D cultures on Matrigel: round (n = 31), stellate (n = 5), and grape-like (n = 4). The latter two morphologies were significantly frequent in the non-BE phenotype (1/23 BE, 8/17 non-BE, p = 0.0014), and the stellate morphology was only found in the non-BE phenotype. SMARCA4 mutations were significantly frequent in stellate-shaped cells (4/4 stellate, 4/34 non-stellate, p = 0.0001). Next, from the 40 cell lines, we successfully established 28 xenograft tumors (18 BE and 10 non-BE) in NOD/SCID mice and classified histological patterns of the xenograft tumors into three groups: solid (n = 20), small nests in desmoplasia (n = 4), and acinar/papillary (n = 4). The latter two patterns were characteristically found in the BE phenotype. The non-BE phenotype exhibited a solid pattern with significantly less content of alpha-SMA-positive fibroblasts (p = 0.0004) and collagen (p = 0.0006) than the BE phenotype. Thus, the morphology of the tumors in 3D cultures and xenografts, including stroma genesis, reflects the intrinsic properties of the cancer cell lines. Furthermore, this study serves as an excellent resource for lung adenocarcinoma cell lines, with clinically relevant information on molecular and morphological characteristics and drug sensitivity.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnimalsCell Line, TumorDNA HelicasesHeterograftsHumansLungMiceMice, Inbred NODMice, SCIDNuclear ProteinsReceptor Protein-Tyrosine KinasesTranscription FactorsDNA HelicasesNuclear ProteinsReceptor Protein-Tyrosine KinasesSMARCA4 protein, humanTranscription Factors3D cultureepithelial mesenchymal transitionlung adenocarcinoma cell linesSMARCA4xenograft tumor

Identifiers

PMID36533957
PMCPMC10067422
OpenAlexW4311934338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.